- |||||||||| utomilumab (PF-05082566) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 27, 2023 P1, N=42, Active, not recruiting, Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| monalizumab (IPH2201) / AstraZeneca, Innate
Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, IO biomarker, Metastases: INTERLINK-1: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Feb 16, 2023 P3, N=370, Active, not recruiting, Recruiting --> Completed Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: ICYMI: Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, MSS, unresectable, or mCRC harboring a BRAF V600E mutation. @VanMorrisMD @MDAndersonNews #crcsm https://t.co/DZgTpIh8NM (Twitter) - Feb 15, 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: 🔥Encorafenib, Binimetinib & Cetuximab in 1st line BRAF V600E mutant #colorectalcancer @JCO_ASCO https://t.co/9Ii9etGbte ✅ANCHOR 🗺️phs-2 95 pts 👉ORR 47% 👉mPFS 5.8 mo 👉mOS 18 mo, 67% 2nd line 🤔positive, CTx-free 1st line, but no molecular correlates 🧐BREAKWATER awaited (Twitter) - Feb 15, 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, microsatellite stable, unresectable, or mCRC harboring a BRAF V600E mutation.@VanMorrisMD @MDAndersonNews #crcsm https://t.co/kBiaOV0K3A (Twitter) - Feb 12, 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, Metastases: ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer | Journal of Clinical Oncology https://t.co/HrScQUtvd1 (Twitter) - Feb 11, 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
P2 data, Journal, Metastases: ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF-Mutant Metastatic Colorectal Cancer. (Pubmed Central) - Feb 10, 2023 P2, P3 The ANCHOR CRC study showed that the scientifically driven combination of encorafenib + binimetinib + cetuximab was active in the first-line setting of BRAF-mutated mCRC with a manageable safety profile. Further first-line evaluation is ongoing (ClinicalTrails.gov identifier: NCT04607421).
- |||||||||| Trial completion date, Trial primary completion date: QUantitative Assessment of Swallowing After Radiation (QUASAR) (clinicaltrials.gov) - Feb 10, 2023
P=N/A, N=42, Recruiting, Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Nov 2025 Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Dec 2023
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Therapy with Cetuximab in Laryngeal Carcinoma: May HER1 Be Useful in the Bioselection of Patients? () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_336; BioRT with cetuximab showed a reduction in the risk of lymph node relapse, particularly in the case of HER1 positive tumors, and it allowed to achieve a higher rate of functional larynx preservation and a higher salvageability compared with upfront surgery. Conclusion HER1 analysis could be clinically useful in the bioselection of tumors that may benefit from BioRT with cetuximab, particularly in those with neck node metastatic propensity.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Salvage chemotherapy after immunotherapy in recurrent/metastatic head and neck carcinoma () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_323; In the MVA, only PDL1 status significantly impacted on independent prognostic factor for PFS (HR=0.25; IC95% 0.09-0.72; p=0.010) and OS (HR=0.31; IC95% 0.11-0.90; p 0.031) after adjusting by ECOG. Conclusion The ORR observed with SCT after immunotherapy was higher than expected regarding the pivotal trials, and is associated with better outcomes in terms of PFS and OS, especially in PDL1 positive pts.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Squamous Cell Carcinoma of Unknown Primary: Tonsillectomies, Radiotherapy, and Primary Emergence () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_302; Most patients also received concurrent systemic therapy, primarily platinum based (n=46) or cetuximab (n=1)...Conclusions In this cohort of patients with squamous cell carcinoma of unknown primary of the head and neck, none of whom underwent lingual tonsillectomy, and the majority of whom did not undergo palatine tonsillectomy, there was no patient with primary site emergence on follow-up. These data suggest there is a potential opportunity to minimize surgical procedures and restrict radiotherapy mucosal targets and doses, particularly in patients who present with p16/HPV positive disease.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Outcomes of curative treatment in elderly patients with locally advanced oropharynx cancer () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_253; Two patients were treated with carboplatin and one with cetuximab instead, simultaneously with radiotherapy...There are some limitations of this study that should be noted, first the low number of patients, the lack of analysis of medical comorbidities and treatment interruptions because of toxicities. To sum up, the literature is not consensual about outcomes in elderly patients and more evidence is needed to take further conclusions.
- |||||||||| 5-fluorouracil / Generic mfg.
Response pattern under palliative chemotherapy in R/M HNSCC () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_249; Inclusion criteria consisted of recurrent metastatic head and neck squamous cell carcinoma having received either platinum, 5-FU, cetuximab (PFC) or docetaxel, cisplatin, cetuximab (TPEx) 6 or 4 cycles respectively...It is unclear whether the continuation of chemotherapy over 2/3 cycles translates in a survival benefit. Especially in the light of the treatment associated toxicities and quality of life, short courses of therapy compared with SoC should be prospectively evaluated.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Head and neck cancer treatment: is cetuximab the best option for patients unfit for cisplatin? () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_208; Especially in the light of the treatment associated toxicities and quality of life, short courses of therapy compared with SoC should be prospectively evaluated. Therefore, this work found important severe toxicity with the cetuximab treatment, which makes us think that it
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Real-world R/M HNSCC patients () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_205; Cetuximab was used in 151 patients...Nearly all patients attended oncology consultations and only 66% were followed by a multidisciplinary team, essential for patient treatment and management due to the high complexity of the disease. This study provides the first real-world characterization of R/M HNSCC patients undergoing first line treatment in Portugal contributing to further understanding the therapeutic value of the different treatment modalities in clinical practice settings.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Real-world healthcare resources utilization costs associated with R/M HNSCC patients in Portugal () - Feb 8, 2023 - Abstract #ECHNOICHNO2023ECHNO_ICHNO_204; This study provides the first real-world characterization of R/M HNSCC patients undergoing first line treatment in Portugal contributing to further understanding the therapeutic value of the different treatment modalities in clinical practice settings. Total HCRU costs included chemotherapy (91.4%), cetuximab (54.5%), immunotherapy (17.2%), radiotherapy (26.3%), lab tests (96.5%), imaging exams (92.0%), hospitalisations (68.1%), emergency (59.3%), outpatient consultations (94.4%) and other appointments (59.0%), were estimated as
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker: Exosomes derived from MDR cells induce cetuximab resistance in CRC via PI3K/AKT signaling‑mediated Sox2 and PD‑L1 expression. (Pubmed Central) - Feb 7, 2023 Furthermore, exosomes derived from CRC/MDR cells decreased sensitivity to cetuximab via the activation of PI3K/AKT signaling, which promoted Sox2 and programmed death-ligand 1 (PD-L1) mRNA and protein expression according to reverse transcription-quantitative PCR, western blotting and immunohistochemistry analyses, as well as apoptosis resistance both in vitro and in vivo according to a TUNEL assay. In conclusion, the results of the present study demonstrated that exosomes derived from CRC/MDR cells may promote cetuximab resistance in KRAS wild-type cells via activation of the PI3K/AKT signaling pathway-mediated expression of Sox2 and PD-L1, which will be useful for investigating a potential clinical target in predicting cetuximab resistance.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: Two Cases of Recurrent Colon Cancer with BRAF Mutation (Pubmed Central) - Feb 4, 2023 Case 2, a 67-year-old man with diagnosis of peritoneal dissemination at 8 months after curative resection, received encorafenb and cetuximab (doublet-therapy) with certain effect, nevertheless advanced triplet-therapy with binimetinib was forced to pause due to severe skin disorders and he died on 123 days after recurrence. We considered that closed follow- up should be required after curatively resected colorectal cancers with BRAF mutation for early detection of recurrence, and prompt induction and evaluation of systemic treatment also should be required after unresectable recurrence including careful management with the attention to the features of doublet and triplet-therapy.
|